Pfizer Stock-Based Compensation 2010-2025 | PFE

Pfizer stock-based compensation for the twelve months ending March 31, 2025 was $2.173B, a 54.99% increase year-over-year.

  • Pfizer annual stock-based compensation for 2024 was $0.877B, a 67.05% increase from 2023.
  • Pfizer annual stock-based compensation for 2023 was $0.525B, a 39.79% decline from 2022.
  • Pfizer annual stock-based compensation for 2022 was $0.872B, a 26.23% decline from 2021.

Pfizer Stock-Based Compensation 2010-2025 | PFE

  • Pfizer annual stock-based compensation for 2024 was $0.877B, a 67.05% increase from 2023.
  • Pfizer annual stock-based compensation for 2023 was $0.525B, a 39.79% decline from 2022.
  • Pfizer annual stock-based compensation for 2022 was $0.872B, a 26.23% decline from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$796.4B
Johnson & Johnson (JNJ)$379.5B
AbbVie (ABBV)$306B
Novo Nordisk (NVO)$260.6B
Roche Holding AG (RHHBY)$248.1B
Novartis AG (NVS)$234.2B
Merck (MRK)$196.7B
Sanofi (SNY)$128.6B
Bayer (BAYRY)$23.7B
Innoviva (INVA)$1.1B